University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
8-2014

Bone strength and architecture : pharmacological targeting of
CaMKK2 as a method for enhancing bone quality.
Zachary James Pritchard
University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Pritchard, Zachary James, "Bone strength and architecture : pharmacological targeting of CaMKK2 as a
method for enhancing bone quality." (2014). Electronic Theses and Dissertations. Paper 1156.
https://doi.org/10.18297/etd/1156

This Master's Thesis is brought to you for free and open access by ThinkIR: The University of Louisville's
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of
the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

BONE STRENGTH AND ARCHITECTURE: PHARMACOLOLOGICAL
TARGETING OF CAMKK2 AS A METHOD FOR ENHANCING BONE QUALITY

By

Zachary James Pritchard
B.S. Sierra Nevada College 2011

A Thesis
Submitted to the Faculty of the
School of Medicine at the
University of Louisville
In Partial Fulfillment of the Requirements
For the Degree of

Master of Science

Department of Pharmacology and Toxicology
University of Louisville
Louisville, Kentucky

August 2014

Copyright 2014 by Zachary James Pritchard
All rights reserved

BONE STRENGTH AND ARCHITECTURE: PHARMACOLOLOGICAL
TARGETING OF CAMKK2 AS A METHOD FOR ENHANCING BONE QUALITY
By
Zachary James Pritchard
B.S. Sierra Nevada College 2011

A Thesis Approved on

June 24th, 2014

By the following Thesis Committee

__________________________________
Dr. Uma Sankar
__________________________________
Dr. Michael Voor
__________________________________
Dr. William Pierce

ii

DEDICATION

This thesis is dedicated to my parents and grandparents

iii

ACKNOWLEDGEMENTS
I would like to thank first and foremost my mentor Dr. Uma Sankar. Her
patience and assistance with me has been far and above than one could ask for.
I’d also like to thank the members of Dr. Sankar’s lab, Rachel and Cierra. I thank
Dr. Voor and his lab for teaching me the equipment required for this project and
letting me become part of his lab. I thank Dr. William Pierce for being a part of my
thesis committee and want to thank the Dept. of Pharmacology and Toxicology
for helping me through this process.

iv

ABSTRACT
BONE STRENGTH AND ARCHITECTURE: PHARMACOLOLOGICAL
TARGETING OF CAMKK2 AS A METHOD FOR ENHANCING BONE QUALITY
Zachary James Pritchard
June 24th 2014
Mice lacking or pharmacologically inhibited for calcium/calmodulin-dependent
protein kinase kinase 2 (CaMKK2) have enhanced bone mass and
microarchitecture. This enhanced bone mass and architecture is due to changes
in osteoblast and osteoclast numbers as well as activity. Whether the enhanced
bone mass translated to increased bone quality and strength was further
explored by developing a method to directly test the trabecular strength of the
distal femur. Micro computed tomography (CT)-based measurement of the
length of the epiphysis of the distal femur, aided in its removal, allowing the
exposure of the trabecular bone volume used to determine the microarchitecture
parameters. Following the development of this method, the hypothesis that the
lack or inhibition of CaMKK2 results in enhance bone strength as well as bone
mass could be tested. Our results then show a strong correlation between the
enhanced bone mass and bone strength in animals lacking or acutely inhibited
for CaMKK2.
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CHAPTER 1
INTRODUCTION
Osteoporosis is a pathological condition wherein decreased bone strength
increases the risk of fracture. Bone strength is a term that intertwines bone
quality and bone density. Bone quality refers to the material and architectural
properties of the bone while bone density simply measures the amount of bone
present. Osteoporosis is widely known to accompany aging; specifically in elderly
women. Hormonal changes are the most common contributor of osteoporosis,
with post-menopausal women being the prime example. Osteoporosis, however,
can also be an unintended consequence of treating other illnesses. Patients
taking glucocorticoids are an example, often unintentionally developing
osteoporosis [1, 2]. Osteoporosis is a leading risk factor for a variety of problems,
including fracture. Fracture events range greatly, from simple transverse
fractures to convoluted comminuted fractures. Hip fractures are credited with the
lion’s share of complications and many treatment options are directed towards
these types of fractures in particular [3]. The development of clots and
pneumonia are common after such breaks and are some of the leading problems
faced by hip fracture patients. These fractures are often exacerbated by other
confounding conditions and increase a patient’s risk of mortality after fracture [4].
Thus prevention of fractures remains a principal objective in assisting
osteoporotic patients. Progress towards this goal is predominantly achieved
through maintaining and improving bone strength.
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Addressing osteoporosis requires understanding the underlying processes
that dictate the continuous upkeep of the skeleton. Tasked with this are a variety
of different cells, the two that have garnered the most focus are the osteoblasts
and osteoclasts. Osteoblasts concern themselves with depositing osteoid and
facilitating the mineralization of our bones. Osteoclasts, on the other hand, resorb
bone in response to a complex signaling pathway. The osteoclasts and
osteoblasts each regulate the other and overall, this dynamic process is deemed
“bone remodeling” [5]. The two types of cells work in concert to repair, maintain,
and adjust the skeleton. This process balances itself accordingly throughout
one’s lifetime to meet the body’s demands. Osteoporosis describes a change in
this balance where deposition of bone falls below that of its removal. This results
in net losses of material; generating bone weaknesses resulting in risks to health.
Treating osteoporosis has been concerned with manipulating bone remodeling.
Both lifestyle changes and pharmacological intervention are often part of treating
osteoporosis.
Developing positive life style habits have been important to
decreasing the likelihood of falls. Mechanical stimulation from exercise positively
influences bone remodeling. The resulting influence has both qualities of
anabolic and ant-catabolic qualities treatments[6]. As activity levels decrease
with age, maintaining some level of activity ensures a slower rate of bone loss,
and potentially reverses some of the deleterious effects of osteoporosis.
Supplementing exercise increases one’s awareness, leading to the prevention of
falls. Falls can be avoided with simple exercises that strengthen and improve gait
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and balance [7] or avoiding seasonal hazards such as ice. However, such an
increased sense of mobility can also lead to an increased number of falls due the
increased exposure to risk, thus giving the perception of exercise being
ineffective. Positive changes in diet have also been shown to protect against
osteoporosis. Calcium supplements or increased consumption of calcium rich
food is often prescribed as an aid against osteoporosis. This tactic should not be
limited to the onset of osteoporosis but may be best to act decades in advance.
Dietary measures such as increasing milk consumption in children and
adolescents appear to have a protective effect against the onset and
development of osteoporosis [8]. Vitamin D is often given also as a treatment in
addition to calcium, maximizing calcium absorbed. Both have been shown to
decrease prevalence of fractures [9]. Behavioral modifications are but one aspect
of managing osteoporosis and are often used alongside pharmacological choices
to potentiate long term success.
The primary approaches for pharmacologically addressing osteoporosis
include both anti-resorptive and anabolic treatment strategies. Anti-resorptive
treatments are chiefly tasked with restricting bone reabsorbed during bone
remodeling, resulting in a net gain in bone deposited. Bisphosphonates (BPs) are
the most common anti-resorptive option. BPs act primarily through binding to
calcium and promoting osteoclast apoptosis when encountered, which in turn
lowers the volume of bone removed, allowing more bone to remain [10].
Antiresorption can be accomplished by alternate routes, such as interrupting
signal molecules to osteoclasts. An example for this tactic is Denosumab.
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Denosumab is an inhibitor of nuclear factor kappa b ligand (RANKL). RANKL has
a role in the maturation and propagation of osteoclasts which, if interrupted,
results in a net reduction in bone resorbed [11]. Manipulating bone remodeling in
the resorptive manner however eventually slows the remodeling process and
leads to decreased bone tissue quality. The anabolic option for treatment is more
appealing because it avoids this limitation.
At present, there is only one approved option for anabolic treatment of
osteoporosis. Para-thyroid hormone (PTH) or teriparatide (TPTD) has a
stimulatory effect on bone remodeling and encourages an accelerated rate of
remodeling which can result in an increase in bone quality.
PTH does stimulate bone remodeling, however this influences the entire
bone remodeling system. That is both bone deposition and bone removal are
increased. With intermittent use, PTH can be used to stimulate osteoblast activity
as it binds to osteoblasts, and without continued presence of PTH
osteoclastogenesis is not upregulated allowing for bone deposition and limited
amounts of bone resorption. If PTH is allowed to have continuous high levels
then bone removal would be upregulated also. [12].
Current options for the treatment of osteoporosis help reduce the risk of
fracture and, in some cases, actively enhance bone quality. However, antiresorptive and anabolic treatments have a variety of limitations. For example,
there are a variety of adverse effects ranging from gastrointestinal upset to
unfavorable methods of delivery. These reduce patient compliance s[13].
Potential treatment options of osteoporosis would need to limit the amount of
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side effects and allow for higher patient compliance. Such treatments would be
screened to also include both anabolic and anti-catabolic qualities. One such
option may lie with the serine-threonine kinase CaMKK2.
Calcium/calmodulin-dependent protein kinase kinase two (CaMKK2) is a
member of the CaMK cascade and is activated with the release of intercellular
calcium. CaMKK2 and phosphorylates CaMK1 or CaMK4 and has roles in
regulating energy balance, acting through AMPK [14],. This serine-threonine
kinase family has members that are ubiquitously expressed such as CaMK1 and
CaMK2, but CaMKK2 itself tissue-restricted [15]. Its locations include different
areas of the brain and lower levels of CaMKK2 are expressed in the bone, spleen
and lungs. Expression and the ablation thereof in murine models have been
linked with impairment of memory in males [16] and susceptibility to
schizophrenia [17]. These links to unfavorable conditions or possible adverse
effects of targeting CaMKK2 are paired with distinct benefits. These potential
worrisome drawbacks may be avoided with conditional knockout models or drug
intervention.
Mice deficient in CaMKK2 appear to be protected from diet induced
obesity. This protection extends to glucose intolerance and insulin resistance
derived from influencing macrophages activation and response [15].
Hematopoietic stem cell (HSC) numbers were decreased along with a decreased
total of bone marrow cells. However these reduced populations of HSCs suffer
no difference in proliferation or survival [18]. Animals deficient in CaMKK2 show
an immediate visual difference in their skeletal system; the long bones appear
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paler than wild type animals. This difference investigated further revealed
significant differences in bone cells. Osteoblasts and osteoclasts populations
were inversely altered; osteoblast populations grew whilst osteoclast populations
declined. Osteoclasts additionally displayed fewer nuclei and decreases in their
relative size. Changes present in cellular populations were joined with
significantly increased bone volume. Altering naturally occurring ratios of
osteoblasts and osteoclasts appears to be responsible for promoting the
observed phenotype. Dramatic changes in bone volume signaled that targeting
CaMKK2 may be an option for protecting against osteoporosis.

Experiments

utilizing genetic ablation can often be reproduced in slight with pharmacological
intervention. Inhibition of CaMKK2 can be achieved with the selective inhibitor
STO-609 [19]. This compound is selective not specific; and at higher
concentrations can inhibit other CaMK members. STO-609 was used
successfully to evoke similar effects in wild type animals that were observed in
knockouts. These effects were reflected in both osteoblast and osteoclast
populations, and offered protection from ovariectomy induced osteoporosis [20].
These effects indicated the utility of acutely inhibiting CaMKK2 without the
inherent weaknesses belonging to whole specimen knockouts. Adverse effects
resulting from STO-609 use have yet to be fully described and are being
explored alongside practical applications.
Managing osteoporosis has been both fruitful and troublesome. Many
risks stemming from it can be mitigated with behavioral and pharmacological
intervention. With the options available, any anabolic approach and the
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advantages therein would be valuable in managing osteoporosis. The goal of the
studies described herein is to investigate whether the acute pharmacological
inhibition of CaMKK2 by STO-609 significantly increases bone quality in addition
to having positive impacts on bone volume, resulting in an increase in bone
strength.
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CHAPTER 2
DISTAL FEMUR INDENTATION: AN IMPROVED METHOD FOR
DETERMINING TRABECULAR BONE STRENGTH IN MICE
Introduction
Bones are responsible for a variety of functions ranging from support and
scaffolding and as levers for movement. Hence, the bone must be strong and
capable of supporting the organism. The demands on each organism’s bones
can be similar but unique, depending on the evolutionary adaptation [21, 22].
Different approaches have been developed to determine the strength of bone.
Closely related to other material sciences, compression, tensile and torsional
strength are among the different mechanical properties that are tested in bone
[23, 24]. To effectively test these properties, different types of bone can be used
to model certain situations. Human vertebrae, for example, can be loaded axially
in compression to simulate how the bone will be loaded in vivo.
X-ray and micro-computed tomography (CT) imaging have been used in
conjunction with mechanical testing to obtain a full picture of the
microarchitectural and biomechanical properties of the bone [25]. Mechanical
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properties of the bone can be predicted from its microarchitecture. Thus, virtual
inspection performed in conjunction with biomechanical testing can validate any
potential correlations between image data and mechanical strength.
Because genetically modified mouse models are highly valuable tools in
understanding the molecular pathways regulating bone biology, robust methods
to test mechanical strength of murine long bones are critical. Whereas methods
to test cortical bone strength such as three- and four-point bending tests are welldeveloped, assays that will effectively test trabecular bone strength in murine
long bones are still lacking.

This study is concerned with determining the

strength of murine trabecular bone in the femur. Working with murine bones
offers unique challenges, given the small size of mouse skeletons. Femurs were
chosen because of their size and the relative ease in the way they can be
handled. Moreover, the femur offered a prime area to image using micro-CT
while also being a possible site for mechanical testing. Besides, the small size of
murine femurs precludes the need to sub-sample cubes, as is done with larger
animals [26]. In this study, we developed a novel method of using reliable microCT imaging as a basis for determining mechanical strength of murine trabecular
bone. We used a murine genetic model with predictable differences in
microarchitecture to validate this technique [27].
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Methods
Mice
Five month old male wild-type (WT, n=5) and Camkk2-/- (n=5) mice were
housed in the Baxter II Vivarium at the University of Louisville. The mice were
under a 12-hr light and dark cycle, with food and water provided ad libitum. All
care and experimental procedures were performed according to University of
Louisville (UofL) Institutional Animal Care and Use Committee protocols and in
compliance with NIH guidelines on the use and care of laboratory and
experimental animals.
Micro-computed tomography (Micro-CT)
Micro-CT imaging was performed at the University of Louisville
Orthopaedic Bioengineering Lab with a high resolution CT scanner (Actis HR225‐
150; BIR, Lincolnshire, IL, USA). Individual or groups of femurs were imaged at a
voxel resolution of 7 µm. An approximate length of 5.25 mm was imaged.
Transverse images were processed using both two-dimensional (ImageJ, NIH
Image, Bethesda, MD) and three-dimensional software (VG Studio Max, Volume
Graphics, Heidelberg, DE).
Removal of epiphysis
Transverse micro-CT image stacks, spanning from the first appearance of a
condyle to the base of the epiphysis, were used to determine the length of the
growth plate at the distal end of the femur. With an isotropic voxel resolution of 7
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µm per slice, the numbers of slices encompassing the region were counted
(Figure 1). The epiphysis/metaphysis junction, appearing as a cross with four
chambers on the micro-CT image (slice 177, Figure 1), represents the region
where the trabecular bone begins and is the site of the indentation test. As
shown in Figure 1, the length of the epiphysis was then calculated in mm
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Figure 1. Determination of the indentation site by micro-CT imaging.
Transverse µCT images were reconstructed into 3-dimensional images (top).
Cross-sectional µCT images were counted and converted into a distance in mm
(middle). This distance was used to determine the amount of bone material to be
removed for mechanical testing (bottom).
In order to remove the epiphysis the femurs needed to be properly
mounted. Using a two part epoxy mix (Loctite® Epoxy Quick Set™, Westlake,
OH, USA), each femur was mounted atop and centered on a socket headed #10
cap screw (Fastenal, USA). Using an appropriate amount of epoxy is critical for
proper mounting, and varies based on the sample. Enough epoxy must be used
to create the base that will surround the femur past the metaphysis and even up
to the condyles (Figure 2A). Samples were allowed to cure for 24 hours.

Figure 2. Femurs mounted prior to epiphysis removal. (A) Femurs were
mounted atop a #10 socket headed screw with Loctite® Epoxy and cured for 24
hours.(B) Calculated lengths of the epiphysis were then removed using an
Isomet® diamond sectioning saw
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Removal of the epiphysis was done with a diamond sectioning saw
(Isomet®, Lake Bluff, IL USA). Because the saw is calibrated in inches, we
converted the epiphysis length measurement from mm to inches. The epoxy-set
femur was mounted on the diamond saw and advanced according to the
calculated epiphysis length in inches (Figure 2B). Removal of the epiphysis was
carefully performed to limit stress. A quick cutting speed was used to reduce the
amount of stress the femur underwent, and to avoid disruption of the epoxy
mount.
Indentation
Indentation of distal femoral trabecular bone was performed via blunt
instrumentation. The indenter used to penetrate the cancellous bone was
machined from a ¾ inch bolt into a blunt cylindrical surface, and measured 3 mm
in length and 1 mm in diameter (Figure 3A). The indenter produced 1.27 MPa of
compressive stress for every Newton (N) of force that was applied.
Immediately following the removal of epiphysis, the femur was centered
on a servo-hydraulic load frame (Model 858 Bionix, MTS Corp., Eden Prairie,
MN). Due to the curvature of the femur, it is possible for the indenter to
encounter the cortical bone of the metaphyseal flare during indentation. Hence,
proper alignment of the indenter was important. Centering the indenter is
intuitive, but aligning the indenter to be slightly anterior of dead center is
required.
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The lowest point during the first 1.5 mm of penetration (force X
displacement in millimeters), as shown in the graphs (Figure 3B), is determined
to be the failure of trabecular bone upon indentation. Indentation was performed
by applying force axially at a rate of 1 mm/minute. The maxium depth of the test
was the full 3 mm length of the indenter. However, the first 1.5 mm (1.5 minutes)
is the accepted region of testing, as it measures the strength of the trabecular
microarchitecture (Figure 3Bi). Anything further than than that is disregarded.
Additionally, any ambigiuous local minima were also disregarded (Figure 3Bii).
Data in this case may be suspect due to architechural interference, such as
contacting the cortex. . Visual confirmation of proper indentation of individual
femurs should be performed by micro-CT (Figure 3C)
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Figure 3. Femurs prior to indentation, after indentation and representative
mechanical strength data. (A) Femur with the epiphysis removed and placed
before indentation. The Indenter used is also shown. (B) Strength data gathered
from both acceptable and unacceptable test results. The distinct local minima in
Bi clearly show a failure in trabecular strength. Ambiguous data graphs as shown
in Bii do not easily discern a point of failure. (C) Micro-CT cross-sectional
images showing the femur after indentation.
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Results
The purpose of this study was to develop a robust methodology to measure
trabecular bone strength in murine femurs. We hypothesized that slicing off the
distal femur epiphysis at the exact epiphysis-metaphysis junction would enable
the exposure of the trabecular bone, enabling the accurate measurement of its
strength. To test this idea, we used long bones from mice that are genetically
knocked out for the expression of Ca2+/calmodulin dependent protein kinase
kinase 2 (CaMKK2; Camkk2-/- mice), that possess enhanced trabecular bone
volume in their long bones when compared to age- and sex-matched WT
mice,[27] (Figure 4, Table1). Micro-CT images revealed that the trabecular bone
in Camkk2-/- distal femurs were most concentrated just beneath the growth plate
(Figure 4 – book slice image), presenting us with the right model system to test
our hypothesis.
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Figure 4. Longitudinal cross-sectional images and numerical values
accompanying wild type and Camkk2-/- animals. Shown left are longitudinal
book slices of wild type and knockout femurs. The distribution of bone shows
more trabecular architecture relegated towards the distal end. (Table 1) Detail
the mean values for bone volume fraction, trabecular thickness, and trabecular
separation along with the p-value with each parameter.
Sequential stacked transverse micro-CT sections of the growth plate were
used to determine the length of the distal epiphysis of individual femurs from 5
month-old WT and Camkk2-/- mice (Figure 5 and Table 2). These data were then
converted to length in mm from the distal tip of the femurs, enabling the
determination of accurate cutting lengths (Table 2). Results from the blunt
indentation performed thereafter showed markedly higher trabecular
compression strength in Camkk2-/- distal femurs, compared to WT (Table 2,
Figure 5).
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Figure 5. Individual epiphysis lengths and trabecular strength data. (Table
2) lists individual lengths of the epiphysis and the strength data of each femur.
Shown right are the mean values with standard deviation shown. The data here
have a p-value of 0.058.
It is important to measure individual cutting lengths using micro-CT
imaging, rather than relying on an average value. As indicated in Table 2, the
average values usually exceed individual epiphyseal lengths. This will lead to
cutting too far below the growth plate and missing the area of interest – i.e.,
epiphysis-metaphysis junction where the trabecular bone is concentrated. If an
average cutting length is utilized to expose the trabecular bone, the differences in
trabecular compression strength may no longer be discernable.
Discussion
This paper details a method for determining the strength of trabecular
bone in the distal femur. Accurate measurement of the region of interest
through calculations based on micro-CT imaging, aided in the removal of
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epiphysis and exposure of the trabecular bone at the base of the growth plate
(Figure 1). This enabled the direct testing of the correlation between
microarchitecture and trabecular strength. . With bone distributed more towards
the growth plate, any excess removal of the epiphysis would be reflected in the
strength data.
The strength data also can give clues as to how well the technique
worked. With acceptable local minima, such as Figure 4Bi, a strong correlation
can be observed between trabecular microarchitecture (bone mass) and
trabecular strength. With the data set presented in Figure 5 and Table 2, this
correlation has an r2 coefficient of 0.654 when adjusted for epiphyseal length.
Thus in conclusion, the method described herein offers an improved method for
determining trabecular strength in the distal femurs of mice.
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CHAPTER 3
ACUTE INHIBITION OR LACK OF CAMKK2 ENHANCES BONE MASS,
MICROARCHITECTURE AND STRENGTH IN ADULT MICE
Introduction
The skeleton consists of a multifunctional tissue that protects internal
organs, facilitates coordinated motion through muscle contraction and maintains
physiological Ca2+ homeostasis [28]. Osteoporosis, a severe age-related bone
disease that increases the risk of fragility fractures is characterized by the loss of
skeletal mass, diminished microarchitecture and lower tissue strength [29, 30].
Bone structure and material composition determines its strength, and a number
of environmental, hormonal, metabolic, and genetic determinants during growth
and aging affect the structure and tissue integrity of the bone [31-33]. The
overall skeletal strength is determined by overall bone size, cortical bone porosity
and tissue strength as well as trabecular bone volume fraction, number,
connectivity, thickness, separation and tissue strength [31, 34]. Loss of
trabecular connectivity is one of the early events associated with age and
hormone-loss associated bone loss in humans [35].
The highly porous trabecular bone is found at the proximal and distal ends
of long bones as well as in vertebral bodies and provides supporting strength to
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these weight bearing bones [31]. The microarchitecture and
biomechanical properties of trabecular bone are optimized through active bone
remodeling initiated by osteocytes and executed by osteoclasts and osteoblasts
(reviewed in [32]). The remodeling process is in turn influenced by hormonal,
paracrine and autocrine signals such as estrogen, testosterone, parathyroid
hormone (PTH), insulin-like growth factor 1 (IGF-1), wingless (Wnt), as well as
biomechanical stresses [35-38]. Moreover, studies using global and tissuespecific gene knockout murine models have uncovered specific genetic
influences on bone mass and/or strength [39-54].
We recently identified novel roles for Ca2+/calmodulin (CaM)-dependent
protein kinase kinase 2 (CaMKK2) in the anabolic and catabolic pathways of
bone remodeling [55]. CaMKs are a family of multifunctional serine/threonine

CaMKIV [56-58]. The CaMK signaling cascade is initiated by transient increases
of intracellular Ca2+, that are immediately sensed by the ubiquitous Ca2+ receptor
CaM [14]. The upstream kinases, CaMKK 1 and 2 are activated trough Ca 2+/CaM
binding and in turn phosphorylate CaMKs I and IV on a critical threonine residue
leading to their activation. In addition, CaMKK2 (not CaMKK1) phosphorylates
and activates adenosine mono-phosphate activated protein kinase (AMPK) to coordinate cellular energy balance [59, 60].
CaMKK2 is tissue-restricted and its loss protects mice from diet-induced
obesity, insulin resistance and inflammatory responses [59, 61, 62]. Loss of
CaMKK2 through global gene deletion positively influences osteoblasts and
22

negatively affects osteoclasts, resulting in a net increase of bone mass [55].
Moreover, pharmacological inhibition of CaMKK2 activity using its selective, cellpermeable pharmacological inhibitor STO-609 in wild type (WT) bone marrow
(BM) cells accelerates osteoblast differentiation while inhibiting osteoclasts in
vitro [55, 63]. Furthermore, STO-609 treatment protects mice from ovariectomyinduced bone loss by stimulating osteoblasts and inhibiting osteoclasts [55]. The
consequence of these opposing effects of the absence of CaMKK2 on bone cell
biology is a net increase in trabecular bone mass, that aids in protection from
osteoporosis. However, whether this increased trabecular bone mass translates
into improved weight bearing capacity and biomechanical properties are
outstanding questions.
We hypothesized that the lack and/or acute pharmacological inhibition of
CaMKK2 results in enhanced trabecular bone mass as well as improved bone
architecture and strength. Our objective for the current study was to assess the
trabecular bone microarchitecture as well as trabecular and cortical bone
strength in the long bones of Camkk2-/- mice. We also aimed to determine
whether the acute inhibition of CaMKK2 using STO-609 would trigger new bone
formation in adult WT male mice that are thirty-two week old, an age at which
their trabecular bone mass is in a maintenance phase and/or beginning to
decline [64]. If so, we further wanted to evaluate whether the microarchitecture
and biomechanical strength parameters indicate enhanced bone volume,
trabecular properties and strength in STO-609 treated adult mice.
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Materials and Methods
Mice: WT and Camkk2-/- mice (C57BL/6 background) were housed in the
University of Louisville (UofL) Baxter II Vivarium under a 12-h light, 12-h dark
cycle. Food and water were provided ad libitum. All care and experimental
procedures were performed according to UofL Institutional Animal Care and Use
Committee protocols and in compliance with NIH guidelines on the use and care
of laboratory and experimental animals. Twelve or thirty-two week old male mice
were used in these experiments.
STO-609 treatment of mice: STO-609 was purchased from TOCRIS Bioscience
(Ellisville, MO, USA) and prepared as mentioned previously [55]. Tri-weekly

-609 (n=13) were administered into thirty-two week old WT male mice
for 6 weeks. Long bones were harvested and femurs were utilized for
microcomputed tomography (µCT) and microarchitecture analyses as well as for
the assessment of cortical and trabecular bone strength. Thirty-two week old
male Camkk2-/- mice (n=6) were used as controls for microarchitecture and
strength analyses.
Dynamic bone histomorphometry: Seven and two days before euthanasia, the
saline and STO-609 treated mice were injected via i.p. with calcein (5 mg/ml) and
alizarin red (15 mg/ml) respectively, at 100 µl per mouse. Mice were euthanized
2 days after the alizarin red injection, and decalcified histology and dynamic
histomorphometry were performed on tibiae that were fixed in 70% ethanol.
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Histomorphometric analysis was performed by a blinded observer using
BioQuant OSTEO 2010 software (BioQuant Image Analysis Corporation) and
standard parameters [65].
Micro-CT Imaging: Micro-computed tomography (µCT) imaging was performed
on a high resolution CT scanner (Actis HR225‐150; BIR, Lincolnshire, IL, USA)
located at the University of Louisville Orthopaedic Bioengineering Lab. Up to 3
femurs were imaged simultaneously at an isotropic voxel resolution of 7µm.
Transverse images of femurs covering a length of approximately 5.25 mm were
processed individually for each femur using a combination of two-dimensional
(ImageJ, NIH Image, Bethesda, MD) and three-dimensional (VG Studio Max,
Volume Graphics, Heidelberg, DE) imaging software. Trabecular architectural
properties including bone volume fraction, trabecular thickness and separation
were determined for a standardized region in the distal femoral metaphysis.
Mechanical testing: After the femurs were imaged in the µCT scanner, they were
prepared for mechanical testing to determine cortical bone strength using threepoint bending and cancellous bone strength using blunt indentation. A servohydraulic load frame was used for both mechanical tests (Model 858 Bionix, MTS
Corp., Eden Prairie, MN).
Three-point-bending was performed by placing the femur across an 8 mm
wide support span and loading vertically with a rounded knife edge at the center
of the span contacting the anterior surface of the femoral diaphysis. The loading
was applied at a displacement rate of 1 mm/min until the femur failed. The
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amount of force, F, applied was recorded and the magnitude of the bending
moment at the point of failure could be calculated as:

. Three-

point-bending typically resulted in the femur breaking into two pieces, a proximal
section and a distal section with an oblique or transverse fracture occurring under
the center contact point.
The resulting distal section of the femur was then prepared for a blunt
indentation test to measure the strength of the cancellous bone material in the
distal part of the femoral metaphysis. The distal femur was mounted in the head
of a #10 cap screw using two-part epoxy with the condyles exposed and the shaft
of the femur oriented along the axis of the screw (Figure 2A). This provided a
means to trim the end off of the femur, exposing the sub-epiphyseal cancellous
bone of the distal metaphysis. The screw was mounted in a low-speed diamond
sectioning saw and the blade was advanced to coincide with the position of the
epiphysis as observed on µCT images taken previously. After a flat surface
perpendicular to the shaft axis was exposed, the screw/bone combination was
positioned under the blunt indenter tip fixed to the actuator of the MTS machine.
The exposed cancellous surface was centered under the indenter and the tip was
advanced at a rate of 1mm/min. The displacement and compressive force were
recorded. The depth of indentation was limited to 1.5 mm to avoid contact of the
indenter tip with the cortical wall of the distal metaphysis.
Equations Used with Mechanical Testing: The maximum applied loads in each
type of test can be used as a measure of the cortical and cancellous bone
strength, but, to determine the true tissue strength, some normalization is
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required. The three-point-bending failure moment can be converted to a
maximum tissue stress using the following equation: σb

; where σb

represents stress (in MPa) of the femoral cortical bone tissue, M represents the
maximum applied bending moment (in N•mm), y represents the vertical distance
from the bone axis to the failure surface (in mm), and I represents the 2nd
moment of inertia (in mm4), a geometric property of a beam that defines its
resistance to bending. For blunt indentation, the applied compressive stress, σ c is
determined by the amount of applied force, F, divided by the cross-sectional
area, A, of the 1 mm diameter indenter tip: σc=F/A.
Statistical analysis: All data are represented as average values ± standard
deviation. Statistical comparisons between WT and Camkk2-/- at three months
were by Student’s t-test. Statistical comparisons between saline (WT) and STO609 treated samples and Camkk2-/- samples were by single factor ANOVA and
post-hoc t-test. Differences with p-value < 0.05 were deemed significant.
Results
Trabecular bone microarchitecture in young male mice lacking CaMKK2
As a first step towards understanding whether the lack of CaMKK2
enhanced bone quality, we analyzed the microarchitecture of the distal femurs
from relatively young twelve week old male WT and Camkk2-/- mice (n=10 each)
using micropreviously in eight week old female mice [55], twelve week old male mice lacking
CaMKK2 possessed a significant two-fold higher trabecular bone volume fraction
27

compared to age and sex matched WT mice (Figure 1B). Next we analyzed
trabecular separation (Tr.Sp) and thickness (Tr.Th) as these are key parameters
characterizing the microarchitecture and quality of the trabecular bone, and are
indicative of its weight bearing strength [35]. Accordingly, Tr.Sp was 53% lower
in twelve week old male Camkk2-/- mice compared to WT (Figure 1C). Further,
trabeculae in the distal femurs of Camkk2-/- mice were 30% thicker than those in
age and sex matched WT mice (Figure 1D). Taken together, these data indicate
significantly higher trabecular bone volume and architectural quality in the long
bones of young male Camkk2-/- mice.
Trabecular bone strength in three month-old male Camkk2-/- mice
Ultrastructural features of trabecular bone are optimized by bone
remodeling, a process characterized by osteoclast-induced bone resorption and
osteoblast-mediated bone formation [66]. Complete inhibition of osteoclast
activity results in higher bone volume, but leads to stiff and brittle bones that
break or fracture more easily [28, 32]. On the other hand, higher bone volumes
and stronger bone can be achieved through increased bone formation by
stimulation of osteoblasts without necessarily completely inhibiting osteoclasts
[28, 32]. The lack of CaMKK2 in the present model favors osteoblasts, but the
Camkk2-/- long bones do possess osteoclasts at significantly decreased levels
compared to WT [55]. Therefore, we surmised that the trabecular bone in the
mutant mice is strong with superior biomechanical properties because the
continuing, albeit diminished, osteoclast activity prevents over-mineralization and
brittleness.
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To test this idea, we performed a blunt indentation test of the trabecular
bone of distal femurs from three month or twelve week old male WT and
Camkk2-/- mice. Briefly, the thickness of the epiphysis and distance to the base

analysis. This information was employed to trim the distal femurs to expose the
epiphyseal plates for precise indentation (Figure 2A). The flat 1 mm diameter
indenter tip produced approximately 1.27 MPa of compressive/contact stress for
every 1 N of force applied. The direct blunt indentation strength of trabecular
bone was a significant 62% higher for Camkk2-/- (51.2 MPa) than that of WT
(31.7 MPa) mice (Figure 2B). Thus, the significant increase in epiphyseal
trabecular strength correlated linearly with the enhanced BV/TV and superior
trabecular architecture in 3 month-old male Camkk2-/- mice, in comparison to WT
(Figures 1-2), indicating that the global deletion of CaMKK2 contributes to higher
bone mass and enhanced strength.
Cortical bone strength in young Camkk2-/- male mice
We next assessed the cortical bone strength by three-point-bending to
failure. As shown in Figure 3A, femoral mid-shaft bending strength was
increased by a significant 43% in Camkk2-/- mice (59.4 ± 8.3 N•mm) than that in
WT (41.6 ± 5.7 N•mm) (Figure 3A). The Camkk2-/- femurs are 8% longer and
their mid-shaft diameters are on average 10% wider than WT (Figures 3C-D).
When the differences in cross-sectional area moments of inertia (MOI) between
Camkk2-/- (0.232 ± 0.044 mm4) and WT mice (0.157 ± 0.0345 mm4) were
considered, the cortical bone tissue bending stress was not significantly different
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between Camkk2-/- (129 ± 30 MPa) and WT (122 ± 39 MPa) mice (Figure 3B-C).
Moreover, the similarity in cortical bone thickness between WT (0.46 ± 0.05 mm)
and Camkk2-/- (0.5 ± 0.04 mm) femurs indicate that the differences in
endocortical resorption is offset by increased periosteal apposition in the
knockout (KO) (Figure 3C). Overall, these data indicate that at twelve weeks of
age, the cortical bones in Camkk2-/- mice are stronger than WT.
STO-609 stimulates bone mass accrual in thirty-two week old male mice
An important question arising from these studies is whether an acute
inhibition of CaMKK2 will trigger new bone formation in adult WT male mice at an
age where their trabecular bone mass has begun to decline (compare Figures 1A
and 5A). To this end, we injected thirty-two week old male WT mice with saline
or

-609 for 6 weeks and metabolically labeled the newly formed bone

with calcein and alizarin red, 7 and 2 days respectively, before the end of the
treatment. STO-609 treatment results in markedly elevated calcein and alizarin
red incorporation (Figure 4A), indicating enhanced bone formation. Moreover,
dynamic histomorphometry measurements indicate significant increases in
mineral apposition rate (MAR; +13%) and bone formation rate (BFR; +40%)
following the acute pharmacological inhibition of CaMKK2 in thirty week old mice
(Figure 4B-C). Thus, treatment with STO-609 stimulates osteoblast-mediated
bone formation in the long bones of adult mice.
We next evaluated bone volume and trabecular microarchitecture in thirtytwo week old saline and STO-609 treated WT as well as Camkk2-/-
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analysis. Compared to the twelve week old male cohorts, the thirty-two week old
male WT and Camkk2-/- mice suffered an 11% decline in BV/TV (Compare
Figures 1B and 5B). However, the bone volume in the older Camkk2-/- mice was
still significantly higher (2-fold) than that in age and sex matched WT (Figures
5A-B), suggesting that the enhanced trabecular bone formation in the KO mice
counteracts the age-dependent bone loss. Moreover, a six week regimen of
STO-609 administration in the WT mice resulted in a significant 52.5% increase
in trabecular bone volume fraction (BV/TV) compared to saline treated controls
(Figure 5B). Further, parameters determining trabecular quality were significantly
higher in older Camkk2-/- mice, as trabecular separation was 49% lower and
trabecular thickness was 28% higher than WT (Figures 5C-D). Treatment of
adult WT mice with STO-609 resulted in a 28% reduction in trabecular separation
and a 28% increase in trabecular thickness (Figures 5C-D). Taken together,
these data indicate that acute pharmacological inhibition of CaMKK2 prevents
age-associated bone loss occurring in adult mice.
Bone strength assessment in STO-609 treated adult mice
Having established that STO-609 treatment enhances trabecular bone
mass accrual and trabecular architecture in adult mice that are in a maintenance
or early catabolic phase of bone metabolism, our next question was whether the
STO-609 treated bone possesses superior biomechanical properties and higher
strength. Direct blunt indentation tests (Figure 2A) were performed to assess the
strength of distal femoral trabecular bone from thirty-two week old Camkk2-/- as
well as saline (WT) and STO-609 treated male mice. Our results indicate that
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compared to control (24.9 ± 4.6 MPa); STO-609 treated femurs (37.1 ± 7.8 MPa)
required a significant 48.9% higher force to break the trabecular bone just below
the epiphyseal plate by direct-blunt indentation (Figure 6A). Indeed, the breaking
force of trabecular bone was still significantly higher (+61.4%) in thirty-two week
old Camkk2-/- mice (40.2 ± 3.8 MPa), indicating that the elevated bone mass and
trabecular bone strength is maintained in Camkk2-/- mice even as they age
(Figure 6A).
We then assessed cortical bone strength in these cohorts by the threepoint-bending to failure, and found a significant increase (+24.8%) in femoral
mid-shaft bending strength in STO-609 treated mice (45.2 ± 6 N•mm) compared
to saline-treated WT controls (36.4 ± 7.1 N•mm) (Figure 6B). Consistent with our
observations in younger mice, femurs from thirty-two week old Camkk2-/- mice
possessed a 22.8% higher three point bending moment (44.7 ± 3.8 N•mm) than
WT controls (Figure 6B). Notably, the mid-shaft mediolateral and dorsoventral
inner and outer diameters increased significantly (+14% on average) in STO-609
treated femurs than controls, whereas they were on average 11% higher in
Camkk2-/- (Figure 6C). Accordingly, as indicated in Figure 6C, the crosssectional area moments of inertia (MOI) were significantly higher in STO-609treated WT (0.157 ± 0.03 mm4) and Camkk2-/- (0.17 ± 0.02 mm4), compared to
saline-treated control mice (0.112 ± 0.03 mm4). In contrast to this increase in the
mid-shaft geometry, the cortical bone thickness and three-point-bending stress
were similar among all three cohorts analyzed (Figure 6C-D). Taken together,
these data indicate that the genetic ablation or acute inhibition of CaMKK2
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results in increased bone mass and higher trabecular and cortical bone strength
in young and adult mice.
Discussion
Based on our previous results indicating elevated bone mass subsequent
to enhanced osteoblasts and diminished osteoclasts in mice lacking CaMKK2
[55], we hypothesized that the enhanced bone mass translates into improved
architectural and biomechanical properties. In this study, we compared
biomechanical properties of the trabecular and cortical bone in Camkk2-/- mice as
they aged and asked whether acutely inhibiting CaMKK2 in adult mice that are in
a maintenance or early catabolic phase of bone metabolism stimulated formation
of new bone with superior quality and strength. Indeed, both twelve and thirtytwo week old Camkk2-/- mice possessed significantly higher trabecular bone
volume and thickness as well as diminished separation, indicating the
maintenance of the improved trabecular volume, microarchitecture and weight
bearing capacity with age. Biomechanical analyses show superior trabecular
and cortical bone strength as well as enhanced mid-shaft geometry in young and
adult mice lacking CaMKK2, compared to WT. In contrast to the higher femoral
bending strength in the KO, the cortical thickness and bending stress were
similar in both genotypes. Metabolic labeling studies indicate stimulation of bone
growth in the long bones of thirty-two week old WT mice following the acute
inhibition of CaMKK2 using STO-609. In addition to significantly higher bone
volume, the trabecular bone from STO-609 treated mice was thicker with less
separation compared to age and sex matched saline-treated control mice.
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Additionally, STO-609 treatment significantly enhanced femoral bending strength
as well as the femoral mid-shaft cross-sectional MOI, suggesting periosteal bone
apposition. Taken together, these data indicate that whereas genetic ablation of
CaMKK2 helps in a sustained maintenance of increased bone mass and
trabecular bone strength, a short-term acute inhibition of this kinase reverses
bone loss and promotes trabecular bone mass accrual as well as superior
trabecular and cortical bone strength in adult mice who are in the beginning
stages of age-associated catabolic bone loss. The natural history of the WT
bone quality reduction can be observed by comparing the measures of both
cortical and cancellous bone from the twelve week old mice (Figures 1-3) to
those of the thirty-two week old mice (Figure 5-6).
Our previous report [55] as well as the mechanical testing and imaging
data from this study support the evidence that the lack of or inhibition of CaMKK2
causes an upregulation of osteoblasts as well as a downregulation of
osteoclasts. Maintenance of optimal bone mass and strength is achieved by the
balanced interplay between osteoclasts and osteoblasts that form the bone
multicellular unit (BMU) in conjunction with osteoid-embedded osteocytes [6769]. Bone strength is determined by the balance of activity within the BMU. For
example, during growth, osteoblast activity exceeds osteoclast resorption,
resulting in addition of bone and a net positive balance, whereas this is reversed
in adults resulting in more bone resorption than addition and a negative balance
[33]. Accordingly, over-active remodeling, as observed during aging and other
pathological conditions that impact the bone, leads to incomplete bone filling by
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osteoblasts resulting in excessive porosity, cortical thinning and trabecular
disconnection [69]. This results in osteoporosis and mechanical flaws within the
bone structure; diminishing its strength and rendering it more prone to fragility
fractures [70, 71].
On one hand, administration of antiresorptive therapies will inhibit ageinduced bone loss and the accumulation of mechanical flaws. On the other
hand, complete inhibition of osteoclast activity with or without accompanying
anabolic activity will result in brittle bones, such as in osteopetrosis, that are
prone to cracking [28]. The most ideal anti-osteoporosis therapies will stimulate
osteoblast-mediated anabolic activity while suppressing, but not completely
eliminating osteoclasts. In mature or older individuals experiencing active
remodeling, such a therapy will create a positive BMU balance by stimulating the
formation of new bone with superior architecture and biomechanical properties.
Our imaging data show that when CaMKK2 is either absent or inhibited by the
application of STO-609, the trabecular bone has a greater volume fraction,
greater thickness and less separation. More importantly, administration of STO609 to mature thirty-two week old mice stimulates new bone formation as
indicated by dynamic histomorphometry and increased trabecular thickness as
evidenced by imaging. Indeed, the STO-609 treated thirty-two week old mice
had bone properties similar to twelve week old WT mice. These data clearly
suggest a renewed anabolic bone effect in adult mice following an acute
pharmacological inhibition of CaMKK2. In Camkk2-/- mice and STO-609 treated
adult mice, this anabolic effect is accompanied by superior trabecular bone
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quality and strength, resulting from the limited, but ongoing osteoclast-mediated
remodeling activity which maintains normal bone material properties at the tissue
level.
Further, imaging data for the cortical bone of the femoral shaft also shows
that there was an anabolic effect on the cortical bone in the KO and STO-609
treated mice since the outer mediolateral and dorsoventral mid-shaft diameters
increased significantly compared to age and sex-matched WT mice.
Interestingly, the inner diameters also increased, indicating a continued activity of
the osteoclasts and endocortical bone resorption. However, increased mid-shaft
outer diameters in the KO and STO-609 treated mice suggest that this is
compensated by increased periosteal apposition, resulting in stronger cortices
with increased cross-sectional MOI.
The three-point-bending mechanical testing data support this premise
because the overall femoral bending strength was shown to be higher in
Camkk2-/- and STO-609 treated mice, but the tissue level strength was not
different. Whereas the structural differences in cortical bone are significant,
overall material quality of between the two genotypes is similar, as evidenced by
similar cortical mid-shaft thickness and material bending stress. In other words,
the net anabolic effects of CaMKK2 genetic ablation or pharmacological inhibition
result in significantly higher breaking strength, but the continued remodeling by
osteoclasts, albeit reduced in numbers [55], ensure that the overall material
quality of the newly formed bone is similar to that in WT. Thus, it is likely that the
resulting bone tissue is normal due to continued remodeling, as opposed to
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increased mineralization and brittleness often seen with bisphosphonate therapy
and osteopetrosis [72, 73].
In conclusion, the absence or acute inhibition of CaMKK2 represents a
model that favors osteoblast-mediated bone formation while suppressing
osteoclast activity [55], resulting in increased trabecular bone volume fraction
and better cortical midshaft geometry. The accompanying reduced level of
osteoclast-mediated remodeling activity imparts the newly formed bone with
superior microarchitecture as well as better cancellous compressive and cortical
bending strength. The increased bone volume fraction, trabecular bone quality
and strength as well as cortical bone strength and mid-shaft cross-sectional area
MOI are sustained in Camkk2-/- mice as they matured to a maintenance or early
catabolic phase of bone metabolism. More importantly, the fact that STO-609
administration stimulated osteoblast-mediated bone formation in mature, thirtytwo week old mice, demonstrates the potential utility of therapeutically inhibiting
CaMKK2 to reverse bone loss while improving cortical and trabecular bone
strength in patients with age related bone loss or osteoporosis.
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Figure 1. Twelve week old male Camkk2-/- mice possess elevated trabecular
bone volume fracture and improved microarchitecture. (A) Digital µCT crosssectional images of distal femurs showing enhanced trabecular bone in Camkk2-/mice compared to age and sex-matched WT. Representative images from n=10
each are shown. (B-D) Average µCT measurements of BV/TV (%), Tr. Sp. (µm)
and Tr. Th. (µm) parameters from distal femurs of twelve week old male WT and
Camkk2-/- mice (n=10 each) are shown. Differences with p -values < 0.05
compared to WT were deemed significant.
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Figure 2. Higher trabecular bone strength in younger Camkk2-/- mice. (A)
(Top) Digital photograph showing the direct blunt indentation device comprising
of a flat 1 mm diameter indenter tip positioned above the distal femur mounted on
a #10 cap screw head. (Bottom) Digital µCT images of the epiphyseal region
taken of the same distal femur before and after direct blunt indentation. (B)
Average direct blunt indentation strength ± standard deviation of the trabecular
bone from WT and Camkk2-/- mice (n=10 each) calculated in MPa is shown. The
difference in trabecular bone strength between WT and Camkk2-/- distal femurs is
significant with a p-value of 0.008.
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Figure 3. Lack of CaMKK2 results in increased cortical bone bending
strength and mid-diaphysis geometry without affecting bending stress.
Graphs depicting average three-point (A) bending moment (N.mm) and (B)
bending stress (MPa) ± standard deviation from WT and Camkk2-/- mice (n=10
each). Camkk2-/- femurs possess a significantly higher bending moment (pvalue = 0.008), compared to WT, but the bending stress is similar between the
two genotypes. (C) Table depicting femur mid-shaft parameters measured by
µCT imaging. Average values ± standard deviation from WT and Camkk2-/- mice
(n=10 each) are shown. * denotes where the difference in these parameters
between the two genotypes is statistically significant with a p-value < 0.03. (D)
Average femur length from WT and Camkk2-/- mice (n=10 each) is shown. pvalue = 0.002.
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Figure 4. STO-609 administration stimulates trabecular bone formation in
thirty-two week old adult male mice. (A) Representative calcein and alizarin
red-labelled sections of proximal tibiae from thirty-two week old male mice that
were administered saline or STO-609 for six weeks (400X magnification). (B-C)
Dynamic histomorphometry analysis of trabecular bone formation in proximal
tibiae: mineral apposition rate (MAR) and bone formation rate (BFR). Average
values ± standard deviation from saline (n=5) and STO-609 treated (n=8)
samples are shown. Differences with p-values < 0.05 were deemed significant.
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Figure 5. Increased trabecular bone volume and enhanced
microarchitecture is sustained in adult mice lacking or acutely inhibited for
CaMKK2. (A) Representative digital µCT cross-sectional images of distal femurs
showing enhanced trabecular bone in thirty-two week old week old male
Camkk2-/- (n=5) and STO-609 treated (n=11) mice compared to age and sexmatched saline-treated WT control mice (n=6). Mice were treated for six weeks
with STO-609. (B-D) Average (± standard deviation) µCT measurements of
BV/TV (%), Tr. Sp. (µm) and Tr. Th. (µm) parameters from distal femurs of adult
Camkk2-/- as well as STO and saline-treated WT mice are shown. Differences
with p-values < 0.05 compared to WT were deemed significant.
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Figure 6. Higher trabecular and cortical bone strength in adult Camkk2-/and STO-609-treated WT mice. (A) Average direct blunt indentation strength ±
standard (MPa) of the trabecular bone from thirty-two week old Camkk2-/- (n=5)
as well as saline (n=6) and STO-609-treated mice (n=11) calculated in MPa is
shown. Trabecular blunt indentation strength of Camkk2-/- (p = 0.004) and STO609-treated (p = 0.007) distal femurs were significantly higher than that of WTcontrol. (B) Average 3-point bending moment (N-mm) of femurs from indicated
genotypes are shown. Differences with p-values < 0.05 were deemed significant.
(C) Table showing femur mid-shaft parameters measured by µCT imaging
showing average values ± standard deviation from 32 week old Camkk2-/- (n=5)
as well as saline (n=6) and STO-609-treated mice (n=11). * and @ denote
where the differences with the saline treated WT controls are statistically
significant with a p-value < 0.05. (D) Average three-point bending stress values
± standard deviation (MPa) from adult Camkk2-/- (n=5) as well as saline (n=6)
and STO-609-treated mice (n=11) are depicted. Bending stress was similar
among all three genotypes.
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CHAPTER 4
SUMMARY AND DISCUSSION
Osteoporosis is pathological condition that can be treated in a number of
ways, such as exercise [6] changes in diet [8], and/or by pharmacological
intervention [10-12]. However, pharmacological therapies that are currently
available primarily block bone resorption without inducing the replacement of lost
bone. The next generation anti-osteoporosis therapies will stimulate new bone
formation while inhibiting excessive bone resorption. Such a therapy will be
highly desirable as it will improve bone quantity and quality in patients, lowering
their risk for fragility fractures. Previous studies from our laboratory recently
demonstrated that the genetic ablation or pharmacological inhibition of CaMKK2
results in a net increase in bone mass in mice [20]. Mice deficient in CaMKK2
show an increase in osteoblasts concurrent with a decrease in osteoclasts,
resulting in enhanced trabecular bone volume [20]. The goal of my thesis
research project was to investigate whether the enhanced bone volume and
microarchitecture translated into superior strength. It was hypothesized, as
outlined in Chapter 3, that the increased amount of bone mass would lead to
increase in bone quality and strength. However, very limited numbers of
techniques were available to effectively test trabecular bone strength of mouse
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long bones. Hence to enable us test this hypothesis, we developed an improved
technique to test murine trabecular bone strength and this is described in
Chapter 2.
With micro-CT imaging mechanical properties of bone can be predicted.
This predictable quality of bone was utilized in developing an improved method to
prepare the tissue for distal femur indentation. With a murine genetic model that
has a predictable difference in microarchitecture; it was possible to refine this
method to observe mechanical differences. Indeed, with removal of the epiphysis
at the epiphyseal/metaphyseal junction, it was possible to test the hypothesis that
increased amounts of trabecular bone lead to increased trabecular bone
strength. Chapter 2 concludes that indentation of the distal femur can accurately
depict the correlation between bone volume fraction and bone strength. This
increase showed a strong r2 coefficient of 0.654. With the resulting success of
the technique developed in Chapter 2, it was then possible to test whether or not
the increased mass of bone lead to superior architecture and strength. Overall
Camkk2-/- and STO-609-treated animals showed increased bone quality and
strength over wild type cohorts.

In conclusion with the evidence gathered, this

thesis shows that the absence or pharmacological inhibition of CaMKK2
positively affects bone growth, microarchitecture and strength.
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APPENDIX
CHAPTER 3:
ACUTE INHIBITION OR LACK OF CAMKK2 ENHANCES BONE MASS,
MICROARCHITECTURE AND STRENGTH IN ADULT MICE
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Running Title: CaMKK2 inhibition increases trabecular and cortical bone
strength.
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Abstract
The tissue-restricted multifunctional Ca2+/calmodulin (CaM)-dependent
protein kinase kinase 2 (CaMKK2) has roles in the anabolic and catabolic
pathways of bone remodeling. Specifically, genetic ablation of CaMKK2
positively influences osteoblasts and negatively affects osteoclasts, resulting in a
net increase of bone mass, and its pharmacological inhibition through STO-609
protects mice from ovariectomy-induced osteoporosis. However, it was not
known whether the enhanced bone mass formed in the absence of CaMKK2
59

would possess improved architectural and biomechanical properties. Here we
analyzed biomechanical properties of the long bones in Camkk2-/- mice as they
aged and examined whether acutely inhibiting CaMKK2 in adult mice stimulated
formation of new bone with superior quality and strength. Our results indicate
that mice lacking CaMKK2 possess increased trabecular bone volume fraction
with higher indentation strength and microarchitectural quality. These superior
trabecular biomechanical properties as well as increased cortical bone bending
strength and mid-shaft cross-sectional area moment of inertia (MOI) are
maintained in Camkk2-/- mice as they matured to adults. Moreover, acute
pharmacological inhibition of CaMKK2 using STO-609 promotes trabecular bone
mass accrual as well as improved trabecular and cortical bone strength in adult
mice that are otherwise in an early catabolic phase of bone metabolism. The
reduced level of osteoclast-mediated remodeling activity present in mice lacking
or inhibited for CaMKK2 activity confers the newly formed bone with superior
biomechanical qualities. Thus, pharmacological inhibition of CaMKK2 is a
potential dual action anabolic/anti-catabolic therapeutic strategy to reverse bone
loss while maintaining bone with high quality and strength.
Key words: Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2, STO609, bone strength, direct blunt indentation, 3-point bending moment,
microarchitecture, osteoblasts, osteoclasts.
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